Newsroom

Industry News

6 Jul

Cytori Receives Key Cell Therapy Patent for Scleroderma

Strengthens Global Scleroderma Intellectual Property Portfolio Extends E.U. protection through 2034 SAN DIEGO, July 06, 2017 (GLOBE NEWSWIRE) —  Cytori Therapeutics, Inc. (CYTX) (“Cytori” or the “Company”) announced today the issuance of key patents that strengthen its intellectual property portfolio in the U.S. and Europe. Cytori now has 107...

Read more

3 Jul

Monster Digital and Innovate Biopharmaceuticals Sign Merger Agreement

Effects a public listing of an autoimmune biotechnology company with its first drug expected to enter Phase 3 trials in late 2017 for celiac disease with pivotal data expected by first half 2019 Ulcerative colitis phase 2 clinical trials for INN-108 expected to begin in first half 2018  ...

Read more

29 Jun

Youngevity Debuts Newest Addition to ProLine — Purmeric(TM)

SAN DIEGO, CA–(Marketwired – Jun 29, 2017) – Youngevity International, Inc. ( NASDAQ : YGYI ), a leading omni-direct lifestyle company, is debuting Pürmeric™, the Company’s latest addition to its ProLine product collection . Pürmeric contains 95% curcuminoids from certified organic tumeric root – delivering what is believed to be a greater anti-oxidant capacity than...

Read more

29 Jun

Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program

NEW YORK and CLEVELAND, June 29, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the FDA has granted Orphan Drug Designation (ODD) for Abeona’s ABO-201 program (AAV-CLN3), the AAV-based single intravenous...

Read more

29 Jun

Reminder: Moleculin Announces Conference Call to Discuss Recent New Discovery for Pancreatic Cancer and Business Update

HOUSTON, TX–(Marketwired – June 29, 2017) – Moleculin Biotech, Inc., (MBRX)(“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced a...

Read more

28 Jun

Catalyst Biosciences’ Factor IX Granted Orphan Drug Designation in Europe

SOUTH SAN FRANCISCO, Calif., June 28, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that the European Commission has granted orphan medicinal product designation to CB 2679d/ISU304, a clinical stage drug candidate for hemophilia B....

Read more

Page 4 of 244« First...23456...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address